The effect of activated charcoal on the absorption of fluoxetine, with special reference to delayed charcoal administration. 1996

K Laine, and K T Kivistö, and S Pelttari, and P J Neuvonen
Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland.

The effect of activated charcoal on fluoxetine (40 mg) absorption, with special reference to delayed charcoal administration, was investigated in a randomized study with four parallel groups of eight Healthy volunteers. The first group ingested fluoxetine on an empty stomach with water only (control). The second group received 25 g of activated charcoal as a suspension immediately after fluoxetine. The third and fourth groups took fluoxetine with water and received 25 g of charcoal 2 or 4 hr after fluoxetine. Timed blood samples were taken and plasma fluoxetine and norfluoxetine concentrations were measured by GC for 96 hr. When charcoal was administered immediately after fluoxetine, the AUC (0-96 hr) of fluoxetine was reduced by more than 96% (P < 0.0005) and the Cmax by more than 98% (P < 0.0005). The reduction in the AUC (0-96 hr) and Cmax of norfluoxetine was similar to that of fluoxetine. When the administration of charcoal was delayed 2 or 4 hr, there was a non-significant mean reduction of 16% and 23% in the AUC (0-96 hr) of fluoxetine. Similarly, the Cmax was not significantly reduced by charcoal given 2 or 4 hr later. Also, the half-life of fluoxetine was not significantly reduced (by 25%) by the late administration of charcoal. We conclude that activated charcoal, ingested immediately after fluoxetine, practically completely prevents the gastrointestinal absorption of fluoxetine. However, regardless of the relatively slow absorption of fluoxetine, delaying charcoal administration 2-4 hr greatly reduces its antidotal efficacy.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008297 Male Males
D002606 Charcoal An amorphous form of carbon prepared from the incomplete combustion of animal or vegetable matter, e.g., wood. The activated form of charcoal is used in the treatment of poisoning. (Grant & Hackh's Chemical Dictionary, 5th ed) Activated Charcoal,Actidose,Actidose-Aqua,Adsorba,Carbomix,Charbon,CharcoAid,CharcoCaps,Charcodote,Formocarbine,Insta-Char,Kohle-Compretten,Kohle-Hevert,Kohle-Pulvis,Kohle-Tabletten Boxo-Pharm,Liqui-Char,Norit,Ultracarbon,Charcoal, Activated
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000931 Antidotes Agents counteracting or neutralizing the action of POISONS. Antidote,Theriacs
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
D016666 Fluvoxamine A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. DU-23000,Desiflu,Dumirox,Faverin,Fevarin,Floxyfral,Fluvoxadura,Fluvoxamin AL,Fluvoxamin Stada,Fluvoxamin beta,Fluvoxamin-neuraxpharm,Fluvoxamin-ratiopharm,Fluvoxamina Geminis,Fluvoxamine Maleate,Fluvoxamine Maleate, (E)-Isomer,Fluvoxamine, (Z)-Isomer,Luvox,Novo-Fluvoxamine,Nu-Fluvoxamine,PMS-Fluvoxamine,ratio-Fluvoxamine,DU 23000,DU23000,Fluvoxamin neuraxpharm,Fluvoxamin ratiopharm,Geminis, Fluvoxamina,Novo Fluvoxamine,Nu Fluvoxamine,PMS Fluvoxamine,ratio Fluvoxamine

Related Publications

K Laine, and K T Kivistö, and S Pelttari, and P J Neuvonen
December 1978, European journal of clinical pharmacology,
K Laine, and K T Kivistö, and S Pelttari, and P J Neuvonen
September 1976, Pediatrics,
K Laine, and K T Kivistö, and S Pelttari, and P J Neuvonen
September 1991, Human & experimental toxicology,
K Laine, and K T Kivistö, and S Pelttari, and P J Neuvonen
December 1977, Lancet (London, England),
K Laine, and K T Kivistö, and S Pelttari, and P J Neuvonen
July 2017, Clinical pharmacokinetics,
K Laine, and K T Kivistö, and S Pelttari, and P J Neuvonen
November 1990, British journal of clinical pharmacology,
K Laine, and K T Kivistö, and S Pelttari, and P J Neuvonen
January 2001, Bollettino chimico farmaceutico,
K Laine, and K T Kivistö, and S Pelttari, and P J Neuvonen
January 2001, American journal of therapeutics,
K Laine, and K T Kivistö, and S Pelttari, and P J Neuvonen
February 1996, The Tokai journal of experimental and clinical medicine,
K Laine, and K T Kivistö, and S Pelttari, and P J Neuvonen
May 1997, Journal of pharmaceutical sciences,
Copied contents to your clipboard!